Dipal Doshi - Jan 13, 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
President and CEO, Director
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Jan 13, 2022
Transactions value $
$17,400
Form type
4
Date filed
1/18/2022, 05:01 PM
Previous filing
Oct 28, 2021
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Options Exercise $17.4K +10K +5.73% $1.74* 184K Jan 13, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Stock Option (Right to Buy) Options Exercise $0 -10K -2.44% $0.00 400K Jan 13, 2022 Common Stock 10K $1.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of (i) 170,067 shares of common stock and (ii) 14,393 shares of restricted common stock issued upon early exercise of stock options.
F2 25% of the shares subject to this option vested and became exercisable on December 31, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.